Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2329-2336

  Gumbo, Tawanda ^a,b   Louie, Arnold ^b   Liu, Weiguo ^b   Brown, David ^b   Ambrose, Paul G ^b   Bhavnani, Sujata M ^b   Drusano, George L ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

ACETYLATOR PHENOTYPE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFICACY; ETHNIC GROUP; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ETHNIC GROUPS; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHARMACOGENETICS; TIME FACTORS;

EID: 34447251840     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00185-07     Document Type: Article

References (47)

1. Adams, C. H., C. J. Werely, T. C. Victor, E. G. Hoal, G. Rossouw, and P. D. van Helden. 2003. Allele frequencies for glutathione S-transferase and N-acetyltransferase 2 differ in African population groups and may be associated with oesophageal cancer or tuberculosis incidence. Clin. Chem. Lab. Med. 41:600-605.
2. Berecz, R., A. de la Rubia, P. Dorado, P. Fernandez-Salguero, M. L. Dahl, and A. Llerena. 2003. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 59:45-50.
3. Bernard, S., K. A. Neville, A. T. Nguyen, and D. A. Flockhart. 2006. Inter-ethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126-135.
4. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone. J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
5. Clinical and Laboratory Standards Institute. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Colangeli, R., D. Helb, S. Sridharan, J. Sun, M. Varma-Basil, M. H. Hazbon, R. Harbacheuski, N. J. Megjugorac, W. R. Jacobs, Jr., A. Holzenburg, J. C. Sacchettini, and D. Alland. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829-1840.
7. Dandara, C., C. M. Masimirembwa, A. Magimba, S. Kaaya, J. Sayi, D. K. Sommers, J. R. Snyman, and J. A. Hasler. 2003. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C>T and 590G>A. Pharmacogenetics 13:55-58.
8. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles.
9. Donald, P. R., F. A. Sirgel, F. J. Botha, H. I. Seifart, D. P. Parkin, M. L. Vandenplas, B. W. Van de Wal, J. S. Maritz, and D. A. Mitchison. 1997. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 156:895-900.
10. Donald, P. R., F. A. Sirgel, A. Venter, D. P. Parkin, H. I. Seifart, B. W. Van de Wal, J. S. Maritz, and P. B. Fourie. 2003. Early bactericidal activity of antituberculosis agents. Expert Rev. Anti-Infect. Ther. 1:141-155.
11. Donald, P. R., F. A. Sirgel, A. Venter, D. P. Parkin, H. I. Seifart, B. W. Van de Wal, C. Werely, P. D. van Helden, and J. S. Maritz. 2004. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin. Infect. Dis. 39:1425-1430.
12. Dong, Y., X. Zhao, B. N. Kreiswirth, and K. Drlica. 2000. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2581-2584.
13. Drusano, G. L., A. Louie, M. Deziel, and T. Gumbo. 2006. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin. Infect. Dis. 42:525-532.
14. Evans, D. A., K. A. Manley, and V. A. McKusick. 1960. Genetic control of isoniazid metabolism in man. Br. Med. J. 2:485-491.
15. Fietta, A., M. Morosini, and A. Cascina. 2001. Effects of continuous or pulsed exposure to rifabutin and sparfloxacin on the intracellular growth of Staphylococcus aureus and Mycobacterium tuberculosis. J. Chemother. 13: 167-175.
16. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
17. Global Alliance for TB Drug Development. 2006. RFP 2006 01. Preclinical evaluation of new drug combinations against tuberculosis. Global Alliance for TB Drug Development, New York, NY.
18. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181.
19. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
20. Gumbo, T., A. Louie, W. Liu, P. G. Ambrose, S. M. Bhavnani, D. Brown, and G. L. Drusano. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis. 195:194-201.
21. Haas, W. H., K. Schilke, J. Brand, B. Amthor, K. Weyer, P. B. Fourie, G. Bretzel, V. Sticht-Groh, and H. J. Bremer. 1997. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob. Agents Chemother. 41:1601-1603.
22. Jayaram, R., R. K. Shandil, S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, E. Kantharaj, and V. Balasubramanian. 2004. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957.
23. Jindani, A., V. R. Aber, E. A. Edwards, and D. A Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
24. Jindani, A., C. J. Dore, and D. A. Mitchison. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
25. Katoh, T., R. Boissy, N. Nagata, K. Kitagawa, Y. Kuroda, H. Itoh, T. Kawamoto, and D. A. Bell. 2000. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int. J. Cancer 85:46-49.
26. Leary, R., R. Jellife, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. IEEE Computer Society, Bethesda, MD.
27. Lee, C. N., and L. B. Heifets. 1987. Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods. Am. Rev. Respir. Dis. 136:349-352.
28. Ma, Q. W., G. F. Lin, J. G. Chen, C. Q. Xiang, W. C. Guo, K. Golka, and J. H. Shen. 2004. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in Shanghai population: occupational and non-occupational bladder cancer patient groups. Biomed. Environ. Sci. 17:291-298.
29. Mitchison, D. A. 1979. Basic mechanisms of chemotherapy. Chest 76:771-781.
30. Ordway, D., M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, M. Martins, J. E. Kristiansen, J. Molnar, and L. Amaral. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922.
31. Parsons, L. M., M. Salfinger, A. Clobridge, J. Dormandy, L. Mirabello, V. L. Polletta, A. Sanic, O. Sinyavskiy, S. C. Larsen, J. Driscoll, G. Zickas, and H. W. Taber. 2005. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob. Agents Chemother. 49:2218-2225.
32. Peloquin, C. A., G. S. Jaresko, C. L. Yong, A. C. Keung, A. E. Bulpitt, and R. W. Jelliffe. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
33. Rieder, H. L. 2002. Interventions for tuberculosis control and elimination. International Union against Tuberculosis and Lung Diseases, Paris, France.
34. Sarma, G. R., S. Kailasam, M. Datta, G. K. Loganathan, F. Rahman, and A. S. Narayana. 1990. Classification of children as slow or rapid acetylators based on concentrations of isoniazid in saliva following oral administration of body-weight and surface-area-related dosages of the drug. Indian Pediatr. 27:134-142.
35. Silva, M. S., S. G. Senna, M. O. Ribeiro, A. R. Valim, M. A. Telles, A. Kritski, G. P. Morlock, R. C. Cooksey, A. Zaha, and M. L. Rossetti. 2003. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J. Clin. Microbiol. 41:4471-4474.
36. Sindelar, G., X. Zhao, A. Liew, Y. Dong, T. Lu, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44: 3337-3343.
37. Sirgel, F. A., P. R. Donald, J. Odhiambo, W. Githui, K. C. Umapathy, C. N. Paramasivan, C. M. Tam, K. M. Kam, C. W. Lam, K. M. Sole, and D. A. Mitchison. 2000. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J. Antimicrob. Chemother. 45:859-870.
38. Suo, J., C. E. Chang, T. P. Lin, and L. B. Heifets. 1988. Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan. Am. Rev. Respir. Dis. 138:999-1001.
39. Tam, C. M., S. L. Chan, K. M. Kam, R. L. Goodall, and D. A. Mitchison. 2002. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int. J. Tuberc. Lung Dis. 6:3-10.
40. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51: 744-747.
41. Varma, M., S. Kumar, A. Kumar, and M. Bose. 2002. Comparison of Etest and agar proportion method of testing drug susceptibility of M. tuberculosis. Indian J. Tuberc. 490:217-220.
42. Viveiros, M., I. Portugal, R. Bettencourt, T. C. Victor, A. M. Jordaan, C. Leandro, D. Ordway, and L. Amaral. 2002. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2804-2810.
43. Weiner, M., D. Benator, W. Burman, C. A. Peloquin, A. Khan, A. Vernon, B. Jones, C. Silva-Trigo, Z. Zhao, and T. Hodge. 2005. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin. Infect. Dis. 40: 1481-1491.
44. Weiner, M., W. Burman, A. Vernon, D. Benator, C. A. Peloquin, A. Khan, S. Weis, B. King, N. Shah, and T. Hodge. 2003. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am. J. Respir. Crit. Care Med. 167:1341-1347.
45. World Health Organization. 2004. Global burden of disease estimates. DTH6 2002Rev. http://www.who.int/healthinfo/bodestimates/en/.
46. Yamane, N., I. Nakasone, H. Saitoh, M. Kaneda, M. Shimojima, K. Yamashita, K. Toyoda, and Y. Okazawa. 1998. Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria. Rinsho Byori 46:719-727.
47. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.